TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02080039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Study: NCT02927925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg as intravenous infusion.
Study: NCT00902369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK106-001616
Description: Part1: Dose escalation Part2: Dose expansion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03567616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsule; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
Study: NCT02956044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg
Study: NCT03567616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
Study: NCT03141918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Curcumin
Description: The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day.
Study: NCT02956044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg
Study: NCT01822756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Other names: Gemzar®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Other names: Gemzar®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Other names: Abraxane®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
Study: NCT01006538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epimacular Brachytherapy
Description: Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
Study: NCT00902369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Study: NCT03666715

Intervention type: DRUG
Intervention: Oral Antipsychotics (OAPs)
Description: No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.

Intervention type: DRUG
Intervention: Paliperidone Palmitate 1-Month Formulation (PP1M)
Description: No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
Study: NCT00703989

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: benfotiamine, α-lipoic acid
Description: benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
Study: NCT01006538

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
Study: NCT01953133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Counselling Sessions
Description: 4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
Study: NCT03398798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .014
Description: .014 CuNiTi orthodontic arch wire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .014
Description: .014 CuNiTi orthodontic arch wire
Study: NCT03398798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .016
Description: .016 CuNiTi orthodontic arch wire
Study: NCT03398798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: .016
Description: .016 CuNiTi orthodontic arch wire

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin brackets
Description: Ormco Insignia Metal Twin brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin brackets
Description: Ormco Insignia Metal Twin brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-ligating brackets
Description: Ormco Insignia SL brackets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-ligating brackets
Description: Ormco Insignia SL brackets
Study: NCT03773549

Intervention type: OTHER
Intervention: Virtual reality experience
Description: Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.

Intervention type: OTHER
Intervention: Virtual reality experience
Description: Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
Study: NCT03492021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention_AP-CPT
Description: Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention_PP-PPT
Description: Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
Study: NCT02233998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth Rinse 2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mouth Rinse 3
Study: NCT02564536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: -Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: -From commercial stock
Study: NCT01499849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Description: (4 X 50 mg capsules) 200 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron
Description: 10 mcg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: 10 mcg/kg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: 20 mg PO and 8 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20 mg PO and 8 mg PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (4 X 0 mg capsules) 0 mg PO
Study: NCT04440800

Intervention type: DEVICE
Intervention: Wearable activity tracker - FitBit
Description: Participants will be given a wearable activity tracker and their daily step count recorded. If there is a reduction from baseline of over 1000 steps, the participant will be contacted and an ambulatory review organised if the reduction is not due to a device compliance issue
Study: NCT03736980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100% lactose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100% lactose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100% lactose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100% lactose
Study: NCT02956044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 4 mg glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 4 mg glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin
Study: NCT03832114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Increasing doses of LNP023 up to 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: Increasing doses of LNP023 up to 200 mg.
Study: NCT02478840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: recombinant human alpha-mannosidase
Study: NCT00750191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Transdiscal Radiofrequency Annuloplasty
Description: Adjustment in dosage form, frequency and or duration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Transdiscal Radiofrequency Annuloplasty
Description: interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
Study: NCT02791191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT04376047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Description: The Reverse Trendelenburg position is a position in which patients' hip and knee are not flexed but the head and chest are elevated at 30° than the abdomen and legs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Semi-recumbent position
Description: The semi-recumbent position is an upright positioning of the head and torso at an angle of 45° while legs are lying on the bed.
Study: NCT03197428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
Study: NCT03010891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The bundle of supportive interventions
Description: usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC \> 45 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual NICU care
Description: usual NICU care + positioning + gentle touch +routine KMC \< 20 minutes
Study: NCT03474900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA implant, Bioretec ltd. Finland
Description: The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium elastic stable nail
Description: Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
Study: NCT01373684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: 180 μg per week s.c. for a total duration of 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide analogue
Description: All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
Study: NCT03736980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybine
Description: Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybine
Description: Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybine
Description: Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybine
Description: Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
Study: NCT02513030

Intervention type: PROCEDURE
Intervention: Defibrillation testing during ICD replacement
Study: NCT03696433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Description: The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-salt diet
Description: The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-salt diet
Description: The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-salt diet
Description: The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
Study: NCT02072304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based CBT
Description: A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: supportive care
Description: supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
Study: NCT03848065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine (PCV13)
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Description: Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Description: Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
Description: Single SC dose of 0.5 mL at Visits 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
Study: NCT03668392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
Study: NCT01890434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
Study: NCT01956630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically modified DCs plus CIK cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Donor leukocyte infusions (DLI)
Study: NCT02202512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 high dose
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 low dose
Description: tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1021958
Description: tablets
Study: NCT00522314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIV and ACBT
Study: NCT04146376

Intervention type: OTHER
Intervention: Use of a postpartum diary and additional blood draws
Description: A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken.

Intervention type: DRUG
Intervention: VWF replacement therapy with Wilate
Description: This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are \<100% in the third trimester of pregnancy

Intervention type: DRUG
Intervention: Tranexamic acid
Description: This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD

Intervention type: DRUG
Intervention: Tranexamic acid
Description: This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD

Intervention type: OTHER
Intervention: Use of a postpartum diary and additional blood draws.
Description: A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken.
Study: NCT01339338

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: warming the contrast media
Description: warm the contrast media with 37℃ water-bathing
Study: NCT00522314

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Cycle of Breathing Techniques
Study: NCT06411977

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vegetable juice
Description: Vegetable juice (Fa. Fitrabbit, Voglsam)
Study: NCT01608217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol (delta-THC)
Description: delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (tablet) three times daily for a period of three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg three times daily for a period of 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg three times daily for a period of three weeks
Study: NCT03207178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mixed CD19/CD20 CAR-T Transfer
Description: Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5\*10\^6 cells/kg body weight,separately.
Study: NCT02739529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel
Study: NCT06232148

Intervention type: DEVICE
Intervention: Type of surgery
Study: NCT03267173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cell
Description: Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
Study: NCT05186831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting
Description: Patients will be asked to text their BP. They will receive an automated response to their texts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online patient portal
Description: Patients will be asked to upload their BP to the online patient portal. They will receive information on how to sign up and use the patient portal. Patients can upload their BP readings daily or at the end of the study period.